BLUE News and Press, bluebird bio Inc. From 10/18/21

bluebird bio, Inc. (NASDAQ: BLUE) today announced that October 19, 2021 has been set as the record date for the dividend of shares of common stock of 2seventy to be distributed to bluebird stockholders in order to effect the separation of bluebird bio and 2seventy bio, Inc. into two ind...

Biotech stocks can be volatile to the extreme. Former high-flying stocks can crash on a bad clinical outcome, regulatory review, or new competitor on the market. The interesting part, though, is that some former star biotech stocks can, on occasion, regain their momentum. Beaten-down biotec...

- Company shares detail on stock distribution ratio and planned cash allocation - - New board members appointed - bluebird bio, Inc. (NASDAQ: BLUE) today announced the filing by 2seventy bio of an updated Form 10 Registration Statement with the U.S. Securities and Ex...

A list of 62 recent IPOs have just entered The Russell 2000 small-cap index after index provider FTSE Russell implemented its Q3 recalibrations. Simultaneously, the new entrants will be part of the Russell 3000 index, which represents Wall Street’s 3,000 largest stocks. As pa...

BLA submission based on data from Phase 1/2 and Phase 3 Northstar studies, which represent more than 220 patient-years of experience with beti-cel bluebird bio, Inc . (Nasdaq: BLUE) today announced it has completed the rolling submission of its Biologics License ...

2seventy bio, the planned oncology spin-off of bluebird bio (NASDAQ: BLUE) announced today that it will host a series of investor events to share further detail on its research pipeline and strategy. Session One: An Introduction to 2seventy’s Pipeline; focus on AML [DAR...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips In 2020, the race for the Covid-19 vaccine distorted investment inflows in the biotechnology sector. Back then, emerging biotech stocks tripled or more on hopes that they would come out with a vaccine. Buying interest in ...

Proceeds to support both bluebird bio and 2seventy bio’s pipeline of novel cell therapy programs Business separation of bluebird and 2seventy expected to be completed in October 2021 bluebird bio, Inc. (NASDAQ: BLUE) announced today that it has entered into an...

Gina Consylman appointed chief financial officer, severe genetic disease Marcela Maus named to bluebird bio board of directors bluebird bio and 2seventy bio to hold investor events in September in advance of separation Business separation targeted for October 2...

MaxCyte has become the go-to partner for biotech companies using non-viral cell engineering, aided by its proprietary patented flow electroporation technology. The company has a scalable (licenses and SPLs) business model with recurring revenues. Milestone and royalty payments (at 100...